Cellectar Biosciences, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY September 30, 2023 | FY June 30, 2023 |
|---|---|---|---|---|---|
| Operating income | -$23.0M | -$51.8M | -$39.0M | — | — |
| Cash from operations | -$23.1M | -$47.6M | -$32.4M | — | — |
| Capital expenditure | $5,880 | $104,195 | $864,038 | — | — |
| Free cash flow | -$23.1M | -$47.7M | -$33.2M | — | — |
| Impairments | $0 | $146,000 | $0 | — | — |
| Total assets | $15.0M | $25.5M | $12.1M | $21.6M | $6.5M |
| Total liabilities | $5.1M | $9.8M | $25.9M | $30.3M | $13.5M |
Shares outstanding 8.0M · Free float 83.8%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.